ライフサイエンスコーパス: gastroesophageal reflux

1 Barrett's esophagus segments and persistent gastroesophageal reflux.

2 frequently performed surgical procedure for gastroesophageal reflux.

3 fundoplication for the surgical treatment of gastroesophageal reflux.

4 choanal atresia repair, and/or treatment of gastroesophageal reflux.

5 ergone a fundoplication for the treatment of gastroesophageal reflux.

6 The symptoms are often confused for those of gastroesophageal reflux.

7 esophageal diseases result from uncontrolled gastroesophageal reflux.

8 hincter relaxation is the main mechanism for gastroesophageal reflux.

9 sociated with a two-to threefold increase in gastroesophageal reflux.

10 n, poor overall health, home oxygen use, and gastroesophageal reflux.

11 n, many of the symptoms of EE mimic those of gastroesophageal reflux.

12 esophagus and may work synergistically with gastroesophageal reflux.

13 criteria and two with findings secondary to gastroesophageal reflux.

14 leaks and strictures, gastric dilation, and gastroesophageal reflux.

15 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 point), and depression (+1 p

16 omorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasa

17 dies were selected by using the search terms gastroesophageal reflux, adenocarcinoma, and Barrett's e

18 Although hemifundoplication may prevent gastroesophageal reflux after esophagomyotomy for achala

19 ocephaly, developed intellectual disability, gastroesophageal reflux and a seizure disorder.

20 There were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses o

21 tissue remodeling is associated with chronic gastroesophageal reflux and constitutes a premalignant l

22 BE is associated with chronic gastroesophageal reflux and esophageal cancer.

23 because of both mechanical effects promoting gastroesophageal reflux and nonmechanical effects.

24 also significant improvements in symptoms of gastroesophageal reflux and rhinitis, bronchial reversib

25 wn a positive correlation between pathologic gastroesophageal reflux and those with hiatal hernia or

26 index greater than 4 on pH monitoring and/or gastroesophageal reflux and/or herniated wrap on upper g

27 Infantile colic, gastroesophageal reflux, and constipation are the most c

28 trition because of uncoordinated swallowing, gastroesophageal reflux, and constipation.

29 855 demonstrated that esophagitis was due to gastroesophageal reflux, and Hirsch in 1900 diagnosed an

30 y causes symptoms similar to those seen with gastroesophageal reflux, and is characterized by increas

31 pse include neck flexion, airway secretions, gastroesophageal reflux, and sleep deprivation.

32 ralized anxiety disorder, diabetes mellitus, gastroesophageal reflux, bacterial infection, and bone m

33 is used variably to prevent complications of gastroesophageal reflux, but its effectiveness is unprov

34 ment of patients who fail medical therapy of gastroesophageal reflux, but recurrent gastroesophageal

35 Gastroesophageal reflux causes inflammation and intestin

36 trophy (SMA) notes that patients suffer from gastroesophageal reflux, constipation and delayed gastri

37 ies, including sleep apnea, hypoventilation, gastroesophageal reflux, degenerative joint disease, uri

38 p of these patients is quite important since gastroesophageal reflux, developmental delay, chronic lu

39 ng bowel habit (15%), constipation (13%) and gastroesophageal reflux disease (12%).

40 lipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease (17.3%).

41 The presence of gastroesophageal reflux disease (26%), esophageal strict

42 ere rhinitis (84.0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

43 of diseases such as functional dyspepsia and gastroesophageal reflux disease (e.g. vomiting, disorder

44 gus (n = 1059) with those from subjects with gastroesophageal reflux disease (gastroesophageal reflux

45 .1; 95% confidence interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI,

46 lin, leptin, and ghrelin are associated with gastroesophageal reflux disease (GERD) and Barrett's eso

47 We examined the incidence and predictors of gastroesophageal reflux disease (GERD) and dyspepsia and

48 Skinner to the understanding of gastroesophageal reflux disease (GERD) and its complicat

49 might represent an alternative treatment of gastroesophageal reflux disease (GERD) and may provide d

50 has enormous potential for the treatment of gastroesophageal reflux disease (GERD) and other esophag

51 The advent of the Montreal definition of gastroesophageal reflux disease (GERD) and the Rome III

52 agement of extraesophageal manifestations of gastroesophageal reflux disease (GERD) and to compare th

53 Lung transplant recipients with documented gastroesophageal reflux disease (GERD) are at increased

54 Current diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal an

55 hageal eosinophilia who were thought to have gastroesophageal reflux disease (GERD) but who did not r

56 Management of gastroesophageal reflux disease (GERD) commonly starts w

57 t clear why only a minority of patients with gastroesophageal reflux disease (GERD) develop Barrett's

58 .4)] were included; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

59 However, gastroesophageal reflux disease (GERD) has remained the

60 The histologic changes associated with acute gastroesophageal reflux disease (GERD) have not been stu

61 The aim was to compare recurrence of gastroesophageal reflux disease (GERD) in children rando

62 RAs) are frequently used in the treatment of gastroesophageal reflux disease (GERD) in children; howe

63 ull-thickness plication for the treatment of gastroesophageal reflux disease (GERD) in comparison wit

64 n (TF) can decrease or eliminate features of gastroesophageal reflux disease (GERD) in some patients

65 Gastroesophageal reflux disease (GERD) is a chronic diso

66 Gastroesophageal reflux disease (GERD) is a common diagn

67 Gastroesophageal reflux disease (GERD) is a common medic

68 Gastroesophageal reflux disease (GERD) is a risk factor

69 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor

70 Gastroesophageal reflux disease (GERD) is a very common

71 Gastroesophageal reflux disease (GERD) is associated wit

72 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and in

73 illustrated by the Montreal classification, gastroesophageal reflux disease (GERD) is much more than

74 Gastroesophageal reflux disease (GERD) is prevalent worl

75 ump inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) is reported in up

76 Gastroesophageal reflux disease (GERD) is the most commo

77 Gastroesophageal reflux disease (GERD) is the most preva

78 Gastroesophageal reflux disease (GERD) is the strongest

79 Exclusion criteria included symptoms of gastroesophageal reflux disease (GERD) more than once a

80 Many individuals with gastroesophageal reflux disease (GERD) never visit their

81 f an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it pre

82 is name, currently used for the treatment of gastroesophageal reflux disease (GERD) or completing Hel

83 Most patients with gastroesophageal reflux disease (GERD) report that stres

84 has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite

85 discrepancy reflects a higher prevalence of gastroesophageal reflux disease (GERD) symptoms or a hig

86 assessed the utility of NBI in patients with gastroesophageal reflux disease (GERD) symptoms.

87 Patients with gastroesophageal reflux disease (GERD) who are not respo

88 phagus (cases) were matched to subjects with gastroesophageal reflux disease (GERD) without Barrett's

89 tailed critique of objective measurements of gastroesophageal reflux disease (GERD) would improve man

90 BS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD), 9.7.

91 Gastroesophageal reflux disease (GERD), a condition comm

92 cluding Crohn disease (CrD), celiac disease, gastroesophageal reflux disease (GERD), and eosinophilic

93 frequency of irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive b

94 e upper airways dysfunction syndrome (RUDS), gastroesophageal reflux disease (GERD), and rare cases o

95 rm use of PPIs for three common indications: gastroesophageal reflux disease (GERD), Barrett's esopha

96 sophagus has been proposed for patients with gastroesophageal reflux disease (GERD), but there is lit

97 n several pathophysiological states, such as gastroesophageal reflux disease (GERD), functional dyspe

98 Gastroesophageal reflux disease (GERD), functional dyspe

99 The association of body mass index and gastroesophageal reflux disease (GERD), including its co

100 Barrett esophagus, a complication of gastroesophageal reflux disease (GERD), predisposes pati

101 ients, who had a previous fundoplication for gastroesophageal reflux disease (GERD), underwent reoper

102 Unlike gastroesophageal reflux disease (GERD), whose symptoms c

103 n accurate method for diagnosing adults with gastroesophageal reflux disease (GERD).

104 s for a range of medical disorders including gastroesophageal reflux disease (GERD).

105 only used in the diagnosis and management of gastroesophageal reflux disease (GERD).

106 ctional gastrointestinal disorders (FGD) and gastroesophageal reflux disease (GERD).

107 e existing endoscopy-based interventions for gastroesophageal reflux disease (GERD).

108 a significant increase in the prevalence of gastroesophageal reflux disease (GERD).

109 in the past year has centered on surgery for gastroesophageal reflux disease (GERD).

110 on atypical/extraesophageal manifestation of gastroesophageal reflux disease (GERD).

111 one combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD).

112 s and many do not report typical symptoms of gastroesophageal reflux disease (GERD).

113 the relaxed EGJ was altered in patients with gastroesophageal reflux disease (GERD).

114 en fundoplication (CNF) for the treatment of gastroesophageal reflux disease (GERD).

115 dal anti-inflammatory drugs) and symptoms of gastroesophageal reflux disease (GERD).

116 urgical option for patients with early-stage gastroesophageal reflux disease (GERD).

117 procedure of choice for obese patients with gastroesophageal reflux disease (GERD).

118 y risk factors for both BE and EA is chronic gastroesophageal reflux disease (GERD).

119 responders and treatment-naive patients with gastroesophageal reflux disease (GERD).

120 cations in adults were dysphagia (70.1%) and gastroesophageal reflux disease (GERD)/heartburn (27.1%)

121 We also included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 w

122 n 2002 and 2005 were matched to persons with gastroesophageal reflux disease (GERD; n = 316) and to p

123 nths after fundoplication for PPI-refractory gastroesophageal reflux disease (n = 14 270 degrees LPF

124 (n = 296 cases) were matched to persons with gastroesophageal reflux disease (n = 308) without Barret

125 ad EoE (n = 17), indeterminate EoE (n = 15), gastroesophageal reflux disease (n = 7), or normal esoph

126 Glasgow Coma Scale score <9 (p = .021), and gastroesophageal reflux disease (p = .033).

127 ether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting,

128 uency, severity, and duration of symptoms of gastroesophageal reflux disease among randomly selected

129 er improvement in quality of life related to gastroesophageal reflux disease and a 50% or greater red

130 rs to result in decreased prevalence of both gastroesophageal reflux disease and adenocarcinoma of th

131 and surgical techniques in the management of gastroesophageal reflux disease and constipation also ma

132 patterns from biopsies of patients with EoE, gastroesophageal reflux disease and controls.

133 11,945 patients aged 18 years and older with gastroesophageal reflux disease and erosive esophagitis.

134 allenges to diagnosis, including the role of gastroesophageal reflux disease and proton pump inhibito

135 75-year-old woman with a medical history of gastroesophageal reflux disease and type II diabetes pre

136 e mechanisms involved in the pathogenesis of gastroesophageal reflux disease are complex and multifac

137 The high reoperation rate and incidence of gastroesophageal reflux disease are concerning.

138 pump inhibitors and has focused attention on gastroesophageal reflux disease as a causative factor in

139 We prospectively assessed 100 patients with gastroesophageal reflux disease before and after sphinct

140 iteria consisted of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophagea

141 , screening 50-year-old men with symptoms of gastroesophageal reflux disease by Cytosponge is cost ef

142 emerging disease that is distinguished from gastroesophageal reflux disease by the expression of a u

143 ished before their place in the treatment of gastroesophageal reflux disease can be determined.

144 suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures.

145 Gastroesophageal reflux disease complicated by Barrett e

146 Gastroesophageal reflux disease complicated by Barrett's

147 search into the use of these technologies in gastroesophageal reflux disease continues to accelerate,

148 95% confidence interval [CI]: 1.04-2.67) or gastroesophageal reflux disease controls (OR = 1.61; 95%

149 bjects with gastroesophageal reflux disease (gastroesophageal reflux disease controls, n = 1332), and

150 Early aggressive surgical treatment of gastroesophageal reflux disease decreases the rate of br

151 es for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive

152 ugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, a

153 ecome available in the last 2 years for many gastroesophageal reflux disease endotherapies, providing

154 Most patients with gastroesophageal reflux disease experience symptomatic r

155 rm outcome of ARS in pediatric patients with gastroesophageal reflux disease have shown good to excel

156 months improved in patients with normal GE (Gastroesophageal Reflux Disease Health-Related Quality o

157 imary laparoscopic antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

158 BMI is associated with symptoms of gastroesophageal reflux disease in both normal-weight an

159 re of the height in meters - and symptoms of gastroesophageal reflux disease in persons of normal wei

160 related to the acidic environment caused by gastroesophageal reflux disease in the gastroesophageal

161 Gastroesophageal reflux disease is a common clinical pro

162 Gastroesophageal reflux disease is a highly prevalent ch

163 Gastroesophageal reflux disease is a highly prevalent di

164 Gastroesophageal reflux disease is a prevalent disorder

165 Gastroesophageal reflux disease is common in adults of a

166 w endoscopic therapies have emerged to treat gastroesophageal reflux disease itself.

167 esophageal sphincter (LES) in patients with gastroesophageal reflux disease often has a low resting

168 is (EoE) was historically distinguished from gastroesophageal reflux disease on the basis of histolog

169 ated with EoE (or indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and

170 intravenous therapy in patients with severe gastroesophageal reflux disease or the Zollinger-Ellison

171 We randomly assigned 64 gastroesophageal reflux disease patients to radiofrequen

172 esents a new option for selected symptomatic gastroesophageal reflux disease patients who are intoler

173 5), and more had a >50% improvement in their gastroesophageal reflux disease quality of life score (n

174 Endoscopic therapies for gastroesophageal reflux disease represent a minimally in

175 ted with a relatively high rate of recurrent gastroesophageal reflux disease requiring treatment, dim

176 Symptoms improved in group A, with the Gastroesophageal Reflux Disease Symptom Assessment Scale

177 uency energy delivery significantly improved gastroesophageal reflux disease symptoms and quality of

178 racticed, its value in patients with chronic gastroesophageal reflux disease symptoms is of unproven

179 ng upper endoscopy for patients with chronic gastroesophageal reflux disease symptoms to assess for B

180 men in the United Kingdom with histories of gastroesophageal reflux disease symptoms, assuming the p

181 inistration recently cleared new endoluminal gastroesophageal reflux disease treatments; however, no

182 The history of gastroesophageal reflux disease was highly prevalent in

183 Gastroesophageal reflux disease was identified as an imp

184 De novo gastroesophageal reflux disease was reported in 43.8%.

185 Patients with gastroesophageal reflux disease who have a partial respo

186 structive sleep apnea may be associated with gastroesophageal reflux disease, a strong risk factor fo

187 allergic rhinitis, chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep

188 Risk factors evaluated included gastroesophageal reflux disease, alcohol consumption, sm

189 cent had symptoms of dyspnea, 87 percent had gastroesophageal reflux disease, and 54 percent had nasa

190 lization for asthma, mechanical ventilation, gastroesophageal reflux disease, and aspiration or other

191 lation), and prior diagnoses (eg, pneumonia, gastroesophageal reflux disease, and other comorbidities

192 the individual to irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer diseas

193 treat a variety of gastric disorders such as gastroesophageal reflux disease, autoimmune gastritis, g

194 factors for EAC have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, ob

195 shown to be a safe and effective therapy for gastroesophageal reflux disease, but its effect on the L

196 Symptoms frequently mimic those of gastroesophageal reflux disease, but the diseases are di

197 Risk factors include gastroesophageal reflux disease, central obesity, and sm

198 sing and treating chest pain associated with gastroesophageal reflux disease, correlates abnormal amb

199 terms: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

200 lowing: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

201 l gastrointestinal complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Ba

202 This issue provides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis,

203 of the lower esophagus epithelium related to gastroesophageal reflux disease, is the strongest known

204 a diligent search for an esophageal etiology-gastroesophageal reflux disease, motility abnormalities,

205 itant chemical carcinogen treatment leads to gastroesophageal reflux disease, multilayered epithelium

206 With improved understanding of gastroesophageal reflux disease, newer developments in d

207 on airway disease, including rhinosinusitis, gastroesophageal reflux disease, obesity and dysfunction

208 , including history of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal ble

209 This article is a review of gastroesophageal reflux disease, other types of esophagi

210 Too much acid can lead to gastroesophageal reflux disease, peptic ulcer disease, a

211 premorbid prevalence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infect

212 44 patients (52%) had objective findings of gastroesophageal reflux disease, such as esophagitis.

213 Triggered by gastroesophageal reflux disease, the origin of this meta

214 ic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabet

215 Except for gastroesophageal reflux disease, which showed a higher r

216 for 5.2 million visits annually, followed by gastroesophageal reflux disease, with 4.5 million visits

217 l adenocarcinoma (BEAC) is a complication of gastroesophageal reflux disease, with no effective chemo

218 ministered a modified version of a validated gastroesophageal reflux disease-specific QOL tool to pat

219 Quality of life, measured by the gastroesophageal reflux disease-specific QOL tool, and r

220 llow-up after ARS in pediatric patients with gastroesophageal reflux disease.

221 180-degree LAF for the surgical treatment of gastroesophageal reflux disease.

222 st frequently performed surgical therapy for gastroesophageal reflux disease.

223 ved cells is a novel potential treatment for gastroesophageal reflux disease.

224 drome (IBS) frequently overlap with those of gastroesophageal reflux disease.

225 gents widely prescribed for the treatment of gastroesophageal reflux disease.

226 to evaluate for the presence of concomitant gastroesophageal reflux disease.

227 thereby conclusively distinguishing it from gastroesophageal reflux disease.

228 fundoplication is an effective treatment for gastroesophageal reflux disease.

229 increasingly recognized disease that mimics gastroesophageal reflux disease.

230 ders, including irritable bowel syndrome and gastroesophageal reflux disease.

231 ct patients from developing complications of gastroesophageal reflux disease.

232 itis is a new disease commonly confused with gastroesophageal reflux disease.

233 esophageal motor disorders and treatment of gastroesophageal reflux disease.

234 the association between BMI and symptoms of gastroesophageal reflux disease.

235 relation to the occurrence and management of gastroesophageal reflux disease.

236 and obese persons are at increased risk for gastroesophageal reflux disease.

237 actors usually indicative of severe types of gastroesophageal reflux disease.

238 d-mediated event and a reliable indicator of gastroesophageal reflux disease.

239 directions in the research and treatment of gastroesophageal reflux disease.

240 eading to duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease.

241 ithout Barrett's esophagus or other types of gastroesophageal reflux disease.

242 ery effective and long-lasting treatment for gastroesophageal reflux disease.

243 Obesity is associated with a risk of gastroesophageal reflux disease.

244 the AGA Institute on "Endoscopic Therapy for Gastroesophageal Reflux Disease." It was approved by the

245 is a laryngeal symptom that can be caused by gastroesophageal reflux disease; however, treatment outc

246 cough may have abnormal proximal exposure to gastroesophageal reflux documented by HMII that would ha

247 ers, including nonalcoholic steatohepatitis, gastroesophageal reflux, gallstones, and increased risk

248 oplication on the incidence of postoperative gastroesophageal reflux (GER) after Heller myotomy.

249 The contribution of gastroesophageal reflux (GER) and vagal function to esop

250 Dental erosion is a complication of gastroesophageal reflux (GER) in adults; in children, it

251 Gastroesophageal reflux (GER) is a disorder that is comm

252 The prevalence of abnormal acid gastroesophageal reflux (GER) is higher in patients with

253 Asymptomatic gastroesophageal reflux (GER) is prevalent in children w

254 f a disease engendered more controversy than gastroesophageal reflux (GER), a highly prevalent condit

255 symptom relief, prevalence of post-treatment gastroesophageal reflux (GER), and complications.

256 , the symptoms of EE were often confused for gastroesophageal reflux (GER).

257 sts with erosive tooth wear have significant gastroesophageal reflux (GERD), despite minor reflux sym

258 n the temporal association between cough and gastroesophageal reflux (GOR) in patients in whom non-GO

259 laparoscopically but failure with recurrent gastroesophageal reflux has resulted in the development

260 tocompatibility locus antigen antibodies and gastroesophageal reflux have been associated with poor o

261 sphincter (UES) to simulated or spontaneous gastroesophageal reflux have shown conflicting results.

262 Subjects reporting nocturnal gastroesophageal reflux in both 1999 and 2010 had more N

263 For the first time, mechanisms of gastroesophageal reflux in critically ill mechanically v

264 rtburn with and without regurgitation due to gastroesophageal reflux in the absence of esophageal muc

265 py of gastroesophageal reflux, but recurrent gastroesophageal reflux is a persistent problem that req

266 Gastroesophageal reflux is common among patients with po

267 he diagnosis of cough, LPR, or asthma due to gastroesophageal reflux is difficult, as no criterion st

268 Gastroesophageal reflux is the main risk factor for esop

269 allograft injury from donor-directed Abs or gastroesophageal reflux led to new ColV and KAT Abs post

270 = 8), leiomyomatosis (n = 5), and refractory gastroesophageal reflux (n = 2) who underwent gastric tr

271 discussed: rhinitis, chronic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal

272 As gastroesophageal reflux persists or recurs in 43% of chi

273 There is significant though mild gastroesophageal reflux postoperatively in 46% of patien

274 rative complications, sleep difficulties and gastroesophageal reflux progressively worsened during fo

275 in the postoperative period from SSc-related gastroesophageal reflux, renal impairment, and skin fibr

276 ireflux surgery, 17.7% experienced recurrent gastroesophageal reflux requiring long-term medication u

277 Gastroesophageal reflux scores were higher in overweight

278 , sex, percent predicted FEV1, self-reported gastroesophageal reflux, St. George's Respiratory Questi

279 presenting with extra-esophageal symptoms of gastroesophageal reflux such as chronic cough and asthma

280 based on the modified Rome III criteria) and gastroesophageal reflux symptoms (GERS) in a population-

281 Apoptosis pathway, gastroesophageal reflux symptoms (reflux), higher body m

282 eep apnea and to determine whether nocturnal gastroesophageal reflux symptoms affect the relationship

283 estioned regarding severity of their typical gastroesophageal reflux symptoms and presence of nocturn

284 nal GERD in 1999 (>/=3 episodes of nocturnal gastroesophageal reflux symptoms per week) had an OR of

285 Barrett's esophagus patients with nocturnal gastroesophageal reflux symptoms should be further evalu

286 's esophagus was associated with more severe gastroesophageal reflux symptoms, and nocturnal reflux s

287 al reflux symptoms and presence of nocturnal gastroesophageal reflux symptoms.

288 The rate of gastroesophageal reflux was comparable with prior studie

289 Gastroesophageal reflux was defined by abnormal pH-testi

290 At 6 months, gastroesophageal reflux was evaluated by 24-hour pH test

291 The physiologic link between HH and gastroesophageal reflux was made at the second half of t

292 Gastroesophageal reflux was reported in 50.0% (40 vs 27

293 Objective evidence of gastroesophageal reflux was seen in 46% patients postope

294 Gastroesophageal reflux was the most common GI diagnosis

295 Chronic sinusitis and gastroesophageal reflux were also associated with exacer

296 From 1995 to 2003, 461 patients with gastroesophageal reflux were enrolled in 4 randomized co

297 pump inhibitors (PPIs) are popular drugs for gastroesophageal reflux, which are now available for lon

298 BACKGROUND & AIMS: Central obesity promotes gastroesophageal reflux, which may be related to increas

299 s have failed to demonstrate that preventing gastroesophageal reflux with antireflux surgery halts th

300 Six studies have suggested that gastroesophageal reflux worsens after cholecystectomy.